This is a temporary backup site for TRENDS MENA while our primary website is being restored following a regional disruption affecting Amazon Web Services cloud infrastructure in the GCC.

Search Site

Alujain widens 2025 loss

The increase in loss is due to impairment charges, weaker prices.

Masar 2025 net profit $262m

Higher land plot sales boost revenue and operating income.

Tasnee’s 2025 losses deepen

The petrochemicals' company's revenue also fell 17.7 percent.

DP World 2025 revenue $24.4bn

The profit for the year up 32.2% to reach $1.96bn.

BYD 2025 revenue surges

The EV manufacturer reported net profit of $.3.3bn for 9M 2025.

MODON inks $133 m pact

  • MODON and Vaccine Industrial Company will set up a joint venture factory in Sadeer City to strengthen the pharmaceutical security system.
  • It is in line with MODON's strategy to create an integrated industrial and investment community to attract national and foreign investor partners.

Riyadh, Saudi Arabia – Saudi Authority for Industrial Cities and Technology Zones (MODON) signed a SAR500 million ($133.3m) investment agreement with the Vaccine Industrial Company (Vaccine).

The agreement says both will set up a joint venture factory in Sadeer City to strengthen the pharmaceutical security system and localize the manufacturing of vaccines and vital medicines in Saudi Arabia.

It is in line with MODON’s strategy to create an integrated industrial and investment community to attract national and foreign investor partners.

This includes reinforcing its initiatives and efforts to enhance the sustainability of the industrial sector, in addition to increasing the pharmaceutical sector’s share of GDP and raising the percentage of its exports.

This is as per the objectives of the national industry strategy to make Saudi an attractive hub for quality investments.

The 42,000 square meter plant will create around 150 new jobs and aims to achieve 20% export of seasonal flu virus, COVID-19, chickenpox, and rotavirus vaccines.

This also includes pneumococcal and meningitis vaccines, given the strong demand for Saudi pharmaceutical exports in the Gulf and regional countries.